SCHEMBL6136110

SCHEMBL6136110

COc1ccc(C2=C(C(=O)c3ccc(O[Si](C(C)C)(C(C)C)C(C)C)cc3)c3ccc(OC)cc3CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.44
ESR2 Q92731 2/20 0.44
MAPT P10636 8/20 0.41
SMN1; SMN2 Q16637 7/20 0.41
TP53 P04637 3/20 0.41
KDM4E B2RXH2 4/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
ALPL P05186 1/20 0.40
CLK1 P49759 1/20 0.40
HSD17B10 Q99714 1/20 0.40
GLA P06280 2/20 0.38
RAB9A P51151 4/20 0.38
NPC1 O15118 3/20 0.38
PTAFR P25105 1/20 0.37
ALDH1A1 P00352 3/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3862097 0.89 ESR1 (0.52) ESR1ESR2MAPTSMN1; SMN2TP53
SCHEMBL6135986 0.85 ESR1 (0.58) ESR1ESR2MAPTSMN1; SMN2TP53
SCHEMBL3976908 0.83 ESR1 (0.55) ESR1ESR2MAPTSMN1; SMN2TP53
SCHEMBL7110390 0.81 ALDH1A1 (0.51) ESR1ESR2MAPTSMN1; SMN2TP53
SCHEMBL7111266 0.80 ESR1 (0.47) ESR1ESR2MAPTSMN1; SMN2TP53
SCHEMBL3886456 0.80 ESR1 (0.54) ESR1ESR2SMN1; SMN2ALDH1A1GAA
SCHEMBL8609912 0.79 ESR1 (0.51) ESR1ESR2MAPTSMN1; SMN2TP53
SCHEMBL3861641 0.79 ESR1 (0.55) ESR1ESR2MAPTSMN1; SMN2TP53
SCHEMBL11187364 0.78 ESR1 (0.55) ESR1ESR2MAPTSMN1; SMN2TP53
SCHEMBL3861662 0.78 ESR1 (0.60) ESR1ESR2MAPTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0895989-B1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity LILLY CO ELI (US) 2005-05-18 EP disclosed
US-6509356-B1 Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound ELI LILLY AND COMPANY 2003-01-21 US disclosed
EP-0895989-A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity ELI LILLY AND COMPANY (US) 1999-02-10 EP disclosed